|
Match
|
Document |
Document Title |
|
|
8178302 |
Mouse models for studying and treating hepatocellular and gastrointestinal tumors
A mouse model is provided which is directed to mice bred to have a disruption in the TGF-β signaling pathways which causes tumorigenesis in the liver and gut of the developing mice. The mice ...
|
|
|
8173859 |
Epilepsy model animal
An epilepsy model animal (CHRNA4:S284L) developing spontaneous epileptic seizure during sleep, which is a nonhuman animal established by ontogenesis of a totipotent cell into which a polynucleotide...
|
|
|
8173861 |
Transgenic pig model for a hereditary neurodegenerative autosomal dominant disease
The present invention discloses a non-human animal model for a hereditary autosomal dominant disease. The non-human animal model expresses at least one phenotype associated with the disease and is...
|
|
|
8168854 |
Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression
Transgenic animals containing a nucleic acid sequence encoding TCL1 operably linked to transcriptional control sequences directing expression to B cells are described. Such transgenic animals...
|
|
|
8148599 |
Transgenic non-human animals for pharmacological and toxicological studies
The present invention is directed to the production, breeding and use of transgenic non-human animals such as mice in which specific genes or portions of genes have been replaced by homologues from...
|
|
|
8134044 |
Transgenic reptiles
A transgenic animal such as a transgenic snake or other reptile that expresses a heterologous expression product is described, along with methods of making the same. In general, the animal...
|
|
|
8124831 |
Transgenic mice carrying functional single nucleotide polymorphisms in brain-specific tryptophan hydroxylase
Recombinant or transgenic non-human mammals are described having a mutant tryptophan hydroxylase 2 (Tph2) gene resulting in altered synthesis of 5-hydroxytryptophan and serotonin in the brain. In...
|
|
|
8124067 |
Method for immunotherapy of tumors
A method for making dendritic cells reactive to an antigen comprises obtaining a sample of dendritic cells and contacting the cells with the antigen and at least one Toll-like receptor stimulant....
|
|
|
8124829 |
Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) in brain and uses thereof
The present invention provides for a transgenic non-human animal whose cells contain a DNA sequence comprising: (a) a nerve tissue specific promoter; and (b) a DNA sequence which encodes a receptor...
|
|
|
8110719 |
ABI1 conditional knockout mouse
Genetically engineered conditional knock-out mice having conditional disruption of the Abi1/Hssh3bp1 gene are disclosed along with methods of making and using same.
|
|
|
8088968 |
Transgenic animals for analyzing CYP3A4 cytochrome P450 gene regulation
The invention relates to the generation of non-human transgenic animals comprising a reporter construct for producing a detectable amount of a reporter molecule operably linked to a transcriptional...
|
|
|
8076532 |
Transgenic mouse defective in WW45 function and use in screening compounds for anti-tunour activity
Mechanisms regulating cell proliferation stop and differentiation initiation during the development stage of mammalian embryo, and the proteins involved therein, are presented. Differentiation...
|
|
|
8076531 |
Transgenic animal with monocyte chemotactic protein 1 promoter
The present invention relates to a transgenic animal, which comprises in its genome a recombinant polynucleotide encoding one or more reporter proteins and a monocyte chemotactic protein-1 (MCP-1)...
|
|
|
8071838 |
Targeted and regional cellular ablation in zebrafish
A system including: (i) a methodology for targeted cellular ablation in zebrafish; (ii) a methodology for regional cellular ablation in zebrafish. These methodologies are used to identify genetic...
|
|
|
8071839 |
Transgenic mouse comprising a polynucleotide encoding human or humanized C5aR and methods of production and use
The present invention relates to transgenic non-human mammals comprising a polynucleotide encoding a human or humanized C5aR. The invention also relates to use of the transgenic non-human mammals...
|
|
|
8067664 |
PRO224 gene disruptions, and methods related thereto
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic...
|
|
|
8058502 |
Increasing lifespan by modulation of WWP-1 and UBC-18
Ubiquitin ligase wwp-1 and ubiquitin conjugating enzyme ubc-18 are identified in nematodes as mediators of dietary restriction induced longevity and therefore as targets for modulation of lifespan...
|
|
|
8053627 |
Methods for treating demyelination disorders
This invention is in the field of neurology. Specifically, the invention relates to the discovery and characterization of molecular components that play a role in neuronal demyelination or...
|
|
|
8044259 |
Determining the capability of a test compound to affect solid tumor stem cells
A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in...
|
|
|
8008539 |
Generation of transgenic human soluble amyloid precursor protein alpha expressing mice
The present invention relates to a novel animal model for neurological degenerative diseases, especially autism, relating to overexpression of human secreted APP-alpha. This novel animal model...
|
|
|
8008540 |
Transgenic non-human animal for use in research models for studying Parkinson's disease
The invention relates to a transgenic mouse model with deficient respiratory chain function in dopamine (DA) neurons. By suppressing or deleting the mitochondrial transcription factor A (Tfam) in...
|
|
|
8003847 |
Non-human mutant mammals deficient in Sigma receptors and their applications
The genome of the non-human mutant mammal, deficient in an endogenous Sigma receptor, contains a mutation that comprises a disruption in an endogenous Sigma receptor gene, wherein said gene...
|
|
|
7993627 |
Methods for determining whether a compound alters the amount of at least one αβ (X-41) peptide and the amount of either total αβ or at least one αβ (X-40) peptide produced by a non-human mammal
This invention provides methods of screening compounds for their ability to alter the production of Aβ(x≧41) alone or in combination with Aβ(x≦40). The methods involve administering compounds to ce...
|
|
|
7989675 |
Method of identifying compounds using a transgenic pig model of cystic fibrosis
The present invention provides transgenic, large non-human animal models of diseases and conditions, as well as methods of using such animal models in the identification and characterization of...
|
|
|
7968762 |
Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
A transgenic animal model for evaluating growth, survival and/or metastasis of xenotransplanted normal or tumor cells or tissue is disclosed, in which a human growth factor, hHGF stimulates growth...
|
|
|
7960606 |
Mouse model of chronic heart failure and coronary atherosclerosis regression
An animal model has been developed where the animals can survive myocardial infarctions caused by diet-induced coronary atherosclerosis, and live with chronic heart failure. This animal model is a...
|
|
|
7960605 |
Methods for testing for caloric restriction (CR) mimetics
Methods for treating neurological diseases and for testing Caloric Restriction (CR) mimetics or CR mimetic candidates. In one exemplary method, a CR mimetic candidate is administered to a...
|
|
|
7956237 |
Gene disruptions, compositions and methods relating thereto
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic...
|
|
|
7951989 |
Methods of screening agents for activity using teleosts
The present invention provides methods of screening an agent for activity using teleosts. Methods of screening an agent for angiogenesis activity, toxic activity and an effect cell death activity...
|
|
|
7947866 |
Gene disruptions, compositions and methods relating thereto
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic...
|
|
|
7943296 |
Methods of screening using a natriuretic peptide receptor
This disclosure provides an intracellular fragment of natriuretic peptide receptor A (NPRA), referred to herein as soluble natriuretic peptide receptor-related fragment (sNRF). It is shown herein...
|
|
|
7935500 |
Identifying calcineurin activators for treatment of schizophrenia
The present invention provides targets, methods, and reagents for the diagnosis and treatment of schizophrenia and related conditions. The invention provides methods for the diagnosis of...
|
|
|
7931902 |
Gene disruptions, compositions and methods relating thereto
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic...
|
|
|
7928283 |
Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in nematodes
An object of the present invention is to develop a new alternative splicing reporter system and to provide a method for detecting alternative splicing patterns in a multicellular organism more...
|
|
|
7928284 |
Methods and animal model for analyzing age-related macular degeneration
Methods for testing candidate drugs for treatment of age-related macular degeneration are provided. Ccl2-deficient, and Ccr2-deficient mice are used to determine the effect of candidate drugs and...
|
|
|
7923545 |
Caterpiller gene family
The present invention relates to a new family of structurally and functionally related nucleic acids and proteins, designed the CATERPILLER family, which is characterized by landmark structural...
|
|
|
7919671 |
Method for testing a compound for a therapeutic effect and a diagnostic method
A method for testing compound for a therapeutic effect utilizing a non-human animal or cell having disruption in the prostatic acid phosphatase gene resulting in a decrease or absence in the...
|
|
|
7919670 |
Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) in brain and uses thereof
The present invention provides for a transgenic non-human animal whose cells contain a DNA sequence comprising: (a) a nerve tissue specific promoter; and (b) a DNA sequence which encodes a receptor...
|
|
|
7906701 |
p300 transgenic animal
The present invention relates to a transgenic animal wherein DNA encoding p300 and a promoter exerting its activity in myocardial cells are introduced, and a screening method using the same.
|
|
|
7902421 |
Animal model for schizophrenia
The invention is an animal model which exhibits neuropathological and behavioral features associated with human schizophrenia. The invention also encompasses an in vivo method of preparing an...
|
|
|
7897834 |
Mutation in the rat adenomatous polyposis coli gene within the human mutation hotspot region
A rat with a disrupted Apc (adenomatous polyposis coli) gene is provided. The mutation can include an A to T transversion changing a lysine to a stop codon at codon 1137. Methods of generating the...
|
|
|
7888048 |
P4HAS as modifiers of the IGFR pathway and methods of use
Human P4HA genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of...
|
|
|
7884260 |
Cell-based screen for agents useful for reducing neuronal demyelination or promoting neuronal remyelination
This invention is in the field of neurology. Specifically, the invention relates to the discovery and characterization of molecular components that play a role in neuronal demyelination or...
|
|
|
7858843 |
Gene disruptions, compositions and methods relating thereto
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic...
|
|
|
7846671 |
Methods of screening for agents that modulate the interaction of RGS and Gαq and urinary incontinence
The present invention provides methods that are useful for the treatment or prevention of smooth muscle disorders such as urinary incontinence and compounds that are useful in such methods.
|
|
|
7847146 |
Model for neurodegenerative disorders
The present invention discloses a double transgenic fly that expresses both Tau protein and the human Aβ42 peptide of human amyloid-β precursor protein (APP). The double transgenic flies of the p...
|
|
|
7838726 |
Methods for introducing heterologous cells into fish
The invention provides methods of introducing heterologous cells into fish. After introduction cells remain viable, and in some instances proliferate, for sufficient time to conduct a variety of...
|
|
|
7834238 |
Saspase knockout animal
Knockout animals in which a gene encoding a SASPase has been deleted (hereinafter, referred to as SASPase KO animals) are provided. The SASPase KO animals deficient in expression of functional...
|
|
|
7834237 |
Materials and methods relating to protein aggregation in neurodegenerative disease
Disclosed is a method of inducing or modeling a disease associated with pathological tau protein aggregation. The method can be carried out in vitro and animal models, and may be used to screen for...
|
|
|
7829757 |
SGRF gene-modified mouse
A targeting vector was constructed by replacing exon regions in the SGRF gene with appropriate drug marker genes. This vector was transfected into mouse ES cell lines to obtain chimeric mice, which...
|